Table 2.
The ongoing clinical trials investigate promising new molecules and innovative therapeutic approaches.
| Name of molecule | Category | Trial phase | Target/mechanism | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| Tisagenlecleucel | CAR-T (CD19) | II | CD19 | NCT04234061 |
| CAR-T (CD19) | I, II | CD19 | NCT03676504 | |
| TC-110 | TCR fusion construction | I, II | CD19-CD3 | NCT04323657 |
| Epcoritamab | BiTE therapy | I, II | CD3 × CD20 | NCT03625037 |
| Obinutuzumab | Biologics | II | Anti-CD20 | NCT02736617 |
| Obinutuzumab | Biologics | II | Anti-CD20 | NCT03229382 |
| Ublituximab | Biologics | III, IV | Anti-CD20 | NCT02793583 |
| Palbociclib | CDK inhibitor | II | CDK4/6 | NCT03478514 |
| Parsaclisib | PI3K inhibitor | II | PI3K α/δ | NCT03235544 |
| LOXO-305 | BTK inhibitor | I, II | BTK | NCT03740529 |
| Orelabrutinib | BTK inhibitor | II | BTK | NCT05076097 |
| Chidamide | Histone deacetylation inhibitor | II | HDAC1/2/3/10 | NCT03629873 |
| ONC201 | Akt/ERK inhibitor | I, II | Akt/ERK | NCT02420795 |
| TQ-B3525 | PI3K inhibitor | II | PI3K α/δ | NCT04398953 |
| Parsaclisib | PI3K inhibitor | II | PI3K α/δ | NCT03235544 |
| BGB-10188 | PI3K inhibitor | I, II | PI3K α/δ | NCT04282018 |
| CLR 131 | Radioiodinated therapeutic | II | Cytotoxic radioisotope | NCT02952508 |
| SNS-062 | BTK/ITK inhibitor | I, II | BTK/ITK | NCT03037645 |
| CYT-0851 | RAD51 inhibitor | I, II | Inhibition of cytidine deaminases and DNA repair | NCT03997968 |
| Pembrolizumab | PD-1 antibody | II | Blocking PD-L1 and PD-L2 from interacting with PD-1 | NCT03153202 |
| NVG-111 | BiTE | II | Binding to ROR1/CD3 | NCT04763083 |
| TL-895 | ITK inhibitor | II | Blocking tyrosine kinase | NCT02825836 |
| IGM-2323 | An engineered bispecific IgM antibody | I | Block CD20 | NCT04082936 |
| BP1002 | L-Bcl-2 antisense oligonucleotide | I | Suppressing L-Bcl-2 | NCT04072458 |
BiTE, bispecific T-cell engager; BTK, Bruton’s tyrosine kinase; CAR-T, chimeric antigen receptor-T cell; ITK, irreversible tyrosine kinase; ROR1, receptor tyrosine kinase-like Orphan Receptor 1 ; TCR, T cell receptor; PD-1, program death-1.